首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1288837

全球骨組織肉瘤治療市場研究報告 - 行業分析、規模、佔有率、成長、趨勢和2023至2030年預測

Global Bone Tissue Sarcoma Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年05月01日 | 出版商:

Value Market Research | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

骨組織肉瘤是指發生在連接和包圍其他身體結構（如脂肪、神經和關節內膜）的骨骼和軟組織中的癌症。它在兒童，青少年和年輕人中更常見，主要影響身體的長骨，如腿和手臂。骨組織肉瘤的癥狀可能包括骨痛、通過皮膚感覺到的腫塊、腹痛和腫脹導致疲勞和體重減輕。用於骨組織肉瘤的一些治療方法包括化療、手術、靶向治療、免疫治療、放射治療等。

市場動態：

推動骨組織肉瘤治療需求的關鍵因素是癌症疾病的患病率增加和骨癌（尤其是骨肉瘤）的增加。藥物開發、藥物審批和上市的增加正在激增對這個市場的需求。大公司正專注於戰略聯盟，以確保藥物的可用性，從而推動這一市場的增長。政府越來越多地採取措施提高人們對骨癌的認識，從而擴大了市場需求。醫療保健領域的投資和發展不斷增長以及對醫療保健服務的需求不斷增長，推動了市場增長。相反，與骨癌的診斷和治療相關的高成本可能會阻礙該市場的增長。

該研究報告涵蓋了波特的五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清楚地瞭解行業結構，並在全球範圍內評估競爭吸引力。此外，這些工具還對全球骨組織肉瘤治療市場的每個細分市場進行了包容性評估。骨組織肉瘤治療行業的增長和趨勢為這項研究提供了整體方法。

區域分析：

本節涵蓋了區域前景，強調了骨組織肉瘤治療市場在北美、歐洲、亞太、拉美、中東和非洲的當前和未來需求。此外，該報告重點關注所有突出地區的個別應用部門的需求、估計和預測。

該研究報告還涵蓋了市場中主要參與者的全面概況和對全球競爭格局的深入看法。骨組織肉瘤治療市場的主要參與者包括安進公司、拜耳公司、輝瑞公司、諾華公司、強生服務公司、禮來公司、Debiopharm集團、武田製藥有限公司、霍夫曼-羅氏有限公司、梯瓦製藥、默克公司、百時美施貴寶公司。這一部分包括對競爭格局的整體看法，其中包括各種戰略發展，如主要的合併和收購、未來的能力、夥伴關係、財務概況、合作、新產品的開發、新產品的推出以及其他發展。

如果你有任何定製要求，請寫信給我們。我們的研究團隊可以根據您的需要提供定製報告。

區域前景銷售分析
簡介銷售分析
北美洲銷售分析
- 概述、歷史和預測銷售分析
- 北美地區按部門銷售分析
- 北美地區國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概況、歷史和預測的銷售分析
- 歐洲分部銷售分析
- 歐洲國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概況、歷史和預測的銷售分析
- 亞太地區分部銷售分析
- 亞太地區國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 亞太其他地區銷售分析
拉美地區銷售分析
- 概況、歷史和預測的銷售分析
- 拉美地區分部銷售分析
- 拉美地區國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概況、歷史和預測銷售分析
- 中東和非洲地區分部銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿聯酋銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東和非洲其他地區銷售分析

第十章：骨組織肉瘤治療公司的競爭格局

骨組織肉瘤治療的市場競爭
夥伴關係/合作/協議
合併和收購
新產品發布
其他方面的發展

第十一章：公司簡介

前10名公司佔有率分析
市場集中度
Amgen Inc.
- 公司概況
- 公司收入
- 產品
- 近期發展
Bayer AG
- 公司概況
- 公司收入
- 產品
- 近期發展
Pfizer Inc.
- 公司概覽
- 公司收入
- 產品
- 近期發展
Novartis AG
- 公司概覽
- 公司收入
- 產品
- 近期發展
Johnson & Johnson Services Inc.
- 公司概覽
- 公司收入
- 產品
- 近期發展
Eli Lilly
- 公司概覽
- 公司收入
- 產品
- 近期發展
Debiopharm Group
- 公司概覽
- 公司收入
- 產品
- 近期發展
Takeda Pharmaceutical Company Ltd.
- 公司概覽
- 公司收入
- 產品
- 近期發展
Hoffmann-La Roche Ltd.
- 公司概覽
- 公司收入
- 產品
- 近期發展
Teva Pharmaceutical
- 公司概覽
- 公司收入
- 產品
- 近期發展
Merck & Co
- 公司概覽
- 公司收入
- 產品
- 近期發展
Bristol-Myers Squibb Company
- 公司概覽
- 公司收入
- 產品
- 近期發展情況

注意- 在公司簡介中，財務細節和最近的發展情況取決於可用性，可能不包括私人公司在內。

簡介目錄圖表

Product Code: VMR112110391

Bone tissue sarcoma refers to cancer that occurs in the bone and soft tissues that connect and surround the other body structures such as fat, nerve and lining of the joints. It is more common in children, teenagers and young adults and majorly affects the long bones of the body, like legs and arms. The symptoms of bone tissue sarcoma may include bone pain, a lump felt through the skin, abdominal pain and swelling resulting in fatigue and weight loss. Some of the treatments used for bone tissue sarcoma include chemotherapy, surgery, targeted therapy, immunotherapy, radiation therapy etc.

Market Dynamics:

The key factor driving the demand for bone tissue sarcoma treatment is the increasing prevalence of cancer diseases and the rise in bone cancer, especially osteosarcoma. Rising drug development, drug approvals and launches are surging the demand for this market. Major companies are focusing on strategic alliances to ensure the availability of drugs, thus, propelling the growth of this market. Increasing government initiatives for creating awareness regarding bone cancer among people is expanding the market demand. Growing investment and development in the healthcare sector and rising demand for healthcare services augment market growth. Conversely, the high cost associated with the diagnosis and treatment of bone cancer may hinder the growth of this market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of bone tissue sarcoma treatment. The growth and trends of bone tissue sarcoma treatment industry provide a holistic approach to this study.

Market Segmentation:

This section of the bone tissue sarcoma treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Multiple Myeloma
Osteosarcoma
Chondrosarcoma
Ewing'S Saroma

By Treatment Type

Targeted Therapy
Chemotherapy
Radiation Therapy
Other Therapies

By End-User

Hospitals
Clinics
Diagnostics Centres
Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Bone Tissue Sarcoma Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the bone tissue sarcoma treatment market include Amgen Inc., Bayer AG, Pfizer Inc., Novartis AG, Johnson & Johnson Services Inc., Eli Lilly, Debiopharm Group, Takeda Pharmaceutical Company Ltd., Hoffmann-La Roche Ltd., Teva Pharmaceutical, Merck & Co, Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . BONE TISSUE SARCOMA TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Treatment Type
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL BONE TISSUE SARCOMA TREATMENT MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Multiple Myeloma Historic and Forecast Sales by Regions
6.5 Osteosarcoma Historic and Forecast Sales by Regions
6.6 Chondrosarcoma Historic and Forecast Sales by Regions
6.7 Ewing's Saroma Historic and Forecast Sales by Regions

7 . GLOBAL BONE TISSUE SARCOMA TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

7.1 Overview by Treatment Type
7.2 Historical and Forecast Data
7.3 Analysis by Treatment Type
7.4 Targeted Therapy Historic and Forecast Sales by Regions
7.5 Chemotherapy Historic and Forecast Sales by Regions
7.6 Radiation Therapy Historic and Forecast Sales by Regions
7.7 Other Therapies Historic and Forecast Sales by Regions

8 . GLOBAL BONE TISSUE SARCOMA TREATMENT MARKET SALES ANALYSIS BY END-USER

8.1 Overview by End-user
8.2 Historical and Forecast Data
8.3 Analysis by End-user
8.4 Hospitals Historic and Forecast Sales by Regions
8.5 Clinics Historic and Forecast Sales by Regions
8.6 Diagnostics Centres Historic and Forecast Sales by Regions
8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL BONE TISSUE SARCOMA TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE BONE TISSUE SARCOMA TREATMENT COMPANIES

10.1. Bone Tissue Sarcoma Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF BONE TISSUE SARCOMA TREATMENT INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Amgen Inc.
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Bayer AG
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Pfizer Inc.
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Novartis AG
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Johnson & Johnson Services Inc.
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Eli Lilly
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Debiopharm Group
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Takeda Pharmaceutical Company Ltd.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Hoffmann-La Roche Ltd.
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Teva Pharmaceutical
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. Merck & Co
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments
11.14. Bristol-Myers Squibb Company
- 11.14.1. Company Overview
- 11.14.2. Company Revenue
- 11.14.3. Products
- 11.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表